Kohei shitara (@KoheiShitara) / X

Kohei shitara (@KoheiShitara) / X

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Raghav Sundar (@sundar__raghav) / X

Kohei shitara (@KoheiShitara) / X

ASCO #GI22: Gastric and esophageal cancers, HER2-targeted therapy, immunotherapy, ADCs

Raghav Sundar (@sundar__raghav) / X

Kohei shitara on X: Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.#stomachcancer @OncoAlert

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Margherita Ambrosini (@margheambro1) / X

PDF) Phase 1 trial of zolbetuximab in Japanese patients with CLDN18 .2+ gastric or gastroesophageal junction adenocarcinoma

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Kohei shitara (@KoheiShitara) / X

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology